List of antiretroviral fixed-dose combinations

Source: Wikipedia, the free encyclopedia.
(Redirected from
Fixed-dose combination (antiretroviral)
)

Antiretroviral drugs are used to

pill burden
.

Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.

Brand name(s) Ingredients (INN) Food and Drug Administration (FDA) approval date European Medicines Agency (EMA) approval date Health Canada approval date Company Single-tablet regimen?
NRTIs / NtRTIs NNRTI INSTI PI PK enhancer
Combivir
lamivudine
zidovudine
September 26, 1997 ViiV Healthcare No
Aluvia
(developing countries)
lopinavir ritonavir September 15, 2000 Abbott Laboratories No
Trizivir
abacavir
lamivudine
zidovudine
November 15, 2000 ViiV Healthcare Yes
Kivexa (EU, RU
)
abacavir
lamivudine
August 2, 2004 ViiV Healthcare No
Generics, e.g.,
Triomune
lamivudine
stavudine
nevirapine (not approved) (many companies) Yes
Generics, e.g.,
Duovir-N
lamivudine
zidovudine
nevirapine (not approved) (many companies) Yes
Truvada
emtricitabine
tenofovir disoproxil
August 2, 2004 Gilead Sciences No
Atripla
emtricitabine
tenofovir disoproxil
efavirenz July 12, 2006 Gilead Sciences
Bristol-Myers Squibb
Yes
Eviplera
(EU, RU)
emtricitabine
tenofovir disoproxil
rilpivirine August 10, 2011 Gilead Sciences
Janssen Pharmaceutica
Yes
Stribild
emtricitabine
tenofovir disoproxil
elvitegravir cobicistat August 27, 2012 Gilead Sciences Yes
Triumeq
abacavir
lamivudine
dolutegravir August 22, 2014 ViiV Healthcare Yes
Evotaz
atazanavir cobicistat January 29, 2015 Bristol-Myers Squibb No
Rezolsta
(EU)
darunavir cobicistat January 29, 2015 Janssen Pharmaceutica No
Dutrebis
lamivudine raltegravir February 6, 2015 Merck & Co. No
Genvoya
emtricitabine
tenofovir alafenamide
elvitegravir cobicistat November 5, 2015 Gilead Sciences Yes
Odefsey
emtricitabine
tenofovir alafenamide
rilpivirine March 1, 2016 Gilead Sciences Yes
Descovy
emtricitabine
tenofovir alafenamide
April 4, 2016 Gilead Sciences No
Juluca
rilpivirine dolutegravir November 21, 2017 ViiV Healthcare Yes
Symfi Lo
lamivudine
tenofovir disoproxil
efavirenz February 5, 2018 (Symfi Lo)
March 22, 2018 (Symfi)
Mylan Yes
Biktarvy
emtricitabine
tenofovir alafenamide
bictegravir February 7, 2018 Gilead Sciences Yes
Temixys
lamivudine
tenofovir disoproxil
February 28, 2018 Mylan No
Symtuza
emtricitabine
tenofovir alafenamide
darunavir cobicistat July 17, 2018 Janssen Pharmaceutica Yes
Delstrigo
lamivudine
tenofovir disoproxil
doravirine August 30, 2018 Merck & Co. Yes
Dovato
lamivudine dolutegravir April 8, 2019 ViiV Healthcare Yes
Cabenuva
rilpivirine cabotegravir January 21, 2021 March 18, 2020[1][2] ViiV Healthcare No

References

  1. ^ "Cabenuva Product information". Health Canada. 25 April 2012. Retrieved 22 January 2021.
  2. ^ "ViiV Healthcare announces first global regulatory approval of Cabenuva; the first complete, long-acting, regimen for the treatment of HIV". GSK. Retrieved 23 January 2021.

External links